Thursday, October 24, 2024
12:00pm - 1:00pm
Hybrid Attendance: Research Bldg. 6, 1.206 Auditorium
or
Zoom
https://www.zoomgov.com/s/1609039203?pwd=ZGILbiLGtdLuMnWgX9TrdHhw06tyb2.1
Guest Presenter
Luis Ostrosky-Zeichner, MD, FACP, FIDSA, FSHEA, FECMM
Professor and Memorial Hermann Endowed Chair
Chief, Division of Infectious Diseases
Director, Laboratory of Mycology Research
University of Texas Health Science Center at Houston
Chief Epidemiology Officer
Memorial Hermann Healthcare System
Yeast and Mould for the Internist
Objectives: At this conclusion of this presentation, participants should be able to:
- Describe changes in the epidemiology of invasive fungal infections.
- Become familiar with new diagnostic techniques for fungal infections.
- Enumerate existing and upcoming therapeutic options for invasive fungal infections.
Target Audience and Needs: Internal Medicine faculty, staff, registered nurses, residents, fellows, students, and internists specializing in Allergy & Immunology, Cardiology, Endocrinology, Gastroenterology, General Medicine,
Geriatrics, Hematology & Oncology, Infectious Diseases, Nephrology, Palliative Care, Pulmonary Critical Care & Sleep Medicine, and Rheumatology need to be regularly updated with new research and guidelines regarding the evaluation
and management of medical disorders and implement them in clinical practice to enhance the quality of patient care and improve patient outcomes.
Educational Methods: Educational methods will include lectures, case presentations, literature review, and panel discussion.
Activity Evaluation: Participants may be asked to complete a session evaluation.
Financial Disclosure: The following are reports of relationships with commercial interests by those individuals who are in the position to control the content of this activity.
Dr. Ostrosky-Zeichner has the following financial disclosures to provide.The speaker discloses the following commercial interests: Scynexis, Pulmocide, Pfizer, T2 Biosystems, Eurofins Viracor (Research funding); Melinta, GSK, F2G, Basilea, Pfizer, Gilead, Eurofins Viracor (Consultant). Any potential conflicts for this presentation have been resolved and the speaker attests that the clinical recommendations within this presentation are evidence-based and free of commercial bias (e.g., peer-reviewed literature, adhering to evidence-based practice guidelines)
Accreditation/Credit Designation: The University of Texas Medical Branch is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The University of Texas Medical Branch designates this live activity for a maximum of _1_ AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Everyone is welcome.